It is difficult to explain the increase in LSD1 expression due to EGCG that shows up as a supporting molecule in anticancer therapy, but the role of LSD1 in non-tumor cells may differ from tumor one, as we proved recently investigating the effect of LSD1 silencing on cell cycle of ECs [46] and also, there is no data about participation of LSD1 in reprogramming of normal to tumour endothelial cells (NECs to TECs). The gene discussed is KDM1A; the disease is neoplasm.